This study is testing a new drug called IDE034 in adults with advanced solid tumors that have spread (metastatic) or are locally advanced. These tumors must show specific markers called B7-H3 and PTK7. The study aims to find out how safe IDE034 is, what side effects it might cause, and if it can shrink tumors. We are looking for people with certain cancers like esophageal squamous cell carcinoma, high-grade serous ovarian cancer, head and neck squamous cell carcinoma, colorectal cancer, and castration-resistant prostate cancer. The study will first test different doses of IDE034 to find the safest and most effective amount, then expand to more participants to confirm these findings.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll 150 participants in total.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will follow participants for approximately 20 months in total to assess the drug's effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.